Scientists are exploring a new gene editing approach that could treat dangerously high cholesterol with a single infusion. The therapy targets a specific gene to permanently lower low density lipoprotein (LDL or “bad”) cholesterol, potentially reducing the need for daily pills or repeated injections. Based on a report from Discover Magazine, early research suggests this one time treatment may offer a lasting solution for people with inherited forms of high cholesterol that do not respond well to standard medications.

Key Takeaways

  • The experimental gene editing treatment aims to permanently disable the PCSK9 gene, which regulates LDL cholesterol levels.
  • In animal studies, a single infusion led to significant and sustained reductions in LDL cholesterol.
  • If proven safe and effective in humans, this approach could replace daily statins or periodic PCSK9 inhibitor injections for certain patients.
  • The research is still in early preclinical stages; human trials have not yet been announced.

How the Gene Editing Therapy Works

The treatment uses CRISPR based gene editing to modify the PCSK9 gene in liver cells. Normally, PCSK9 helps break down LDL receptors, leading to higher levels of bad cholesterol in the blood. By editing the gene to stop its activity, the liver can remove more LDL cholesterol from circulation. According to the original report, researchers delivered the gene editing components via a harmless virus that targets the liver. After a single infusion in laboratory animals, PCSK9 levels dropped dramatically and stayed low for months. The findings suggest that a similar approach could work in humans, offering lifelong cholesterol control after just one procedure.

Why This Matters for People With High Cholesterol

Current treatments for high cholesterol include daily statin pills, which many patients struggle to take consistently, and injectable PCSK9 inhibitors that require regular shots. For people with familial hypercholesterolemia, a genetic condition that causes extremely high LDL levels, standard medications may not be enough to lower cholesterol to safe levels. A single infusion that permanently edits the PCSK9 gene could eliminate the need for daily medication and greatly reduce the risk of heart attacks and strokes. The Discover Magazine article notes that researchers see this as a potential game changer for patients who cannot achieve adequate control with existing therapies.

What the Research Shows So Far

Early studies in non human primates and mice have demonstrated that the gene editing infusion can reduce LDL cholesterol by 50% to 60% for more than a year. No serious side effects were reported in these experiments, though longer term safety data are needed. The original report emphasizes that these are preclinical results and that several hurdles remain before human testing can begin. Researchers must ensure that the editing only occurs in liver cells and does not affect other tissues, and they must prove that the virus used to deliver the therapy does not trigger an immune reaction. If those challenges are overcome, clinical trials in humans could start within the next few years.

Frequently Asked Questions

Is this gene editing treatment already available?

No, the treatment is still in early preclinical research. It has been tested only in animals, and human clinical trials have not yet begun. The Discover Magazine report notes that if studies progress, it will likely be several years before the therapy could be approved for general use.

Who would be a candidate for this therapy?

The therapy is being developed primarily for people with inherited forms of high cholesterol, such as familial hypercholesterolemia, that do not respond well to standard treatments. It might also be considered for patients who cannot tolerate statins or who need very large reductions in LDL cholesterol.

Does gene editing for cholesterol have any risks?

As with any gene editing approach, there are risks of unintended edits to other genes, which could cause long term health problems. The delivery method using a virus may also trigger immune reactions. According to the original article, researchers are working to minimize these risks by designing highly specific editing tools and testing safer viral carriers.

This is an original report by Vital Signs Today, informed by reporting from Google News. Read the original source.

This article is for information only and is not medical advice. See our Medical Disclaimer.